Market data shows CRDL stock price has outperformed its peer group year-to-date, with relative strength index readings hinting at further potential upside. Traders should monitor earnings announcements for confirmation of growth catalysts. Because Cardiol Therapeutics isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. Over the last year its cash burn actually increased by a very significant 68%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . According to Spark, TipRanksâ AI Analyst, TSE:CRDL is a Underperform. CRDL stock price short interest has declined, which often signals reduced bearish sentiment. If fundamentals align, the short covering could accelerate price recovery.